Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 198

The DOI matches its Crossref record.

A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization

Open access
Jang, Jeong Won, Choi, Jong Young, Bae, Si Hyun, Yoon, Seung Kew, Chang, Im U, Kim, Chang Wook, Cho, Se Hyun, Han, Jun Yeol, Lee, Young Sok·2006·Hepatology

Abstract

Reactivation of hepatitis B virus (HBV) during chemotherapy is well documented. However, there are limited data on this complication in patients with hepatocellular carcinoma (HCC) undergoing transarterial chemotherapy. The aim of this study was to evaluate the efficacy of preemptive lamivudine therapy in reducing hepatitis due to HBV reactivation in patients with HCC undergoing transarterial chemo-lipiodolization (TACL) and to seek predictors of this event. A total of 73 consecutive HCC patients undergoing TACL using epirubicin 50 mg/m2 and cisplatin 60 mg/m2 at monthly intervals were prospectively and randomly assigned to receive lamivudine 100 mg daily from the start of TACL (preemptive group) or not (control group). During the study, 11 (29.7%) of 37 patients in the control group and 1 (2.8%) of 36 patients in the preemptive group developed hepatitis due to HBV reactivation ( P = .002). In addition, there were significantly more incidences of overall hepatitis ( P = .021) and severe grade of hepatitis ( P = .035) in the control group. With multivariate Cox regression model, a baseline HBV DNA level of more than 104 copies/mL was the only independent predictor of hepatitis due to HBV reactivation during chemo-lipiodolization ( P = .046). In conclusion , preemptive lamivudine therapy demonstrated excellent efficacy in reducing hepatitis due to HBV reactivation and hepatic morbidity during TACL. Preemptive therapy should be considered in HCC patients with an HBV DNA level of more than 104 copies/mL. Further studies are needed to confirm the value of this approach in patients with low-level viremia. (Hepatology 2006;43:233–240.)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.21024

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 198

Metadata

Authors
Jang, J. W., Choi, J. Y., Bae, S. H., Yoon, S. K., Chang, I. U., Kim, C. W., Cho, S. H., Han, J. Y., & Lee, Y. S.
Venue
Hepatology
Published
2006-02
Volume
43
Issue
2
Pages
233-240
ISSN
0270-9139 (ISSN-L)
OpenAlex
W1977303859
Cited by
198
References
0
FWCI
7.53
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. https://app.cochat.ai/papers/10.1002/hep.21024
The paper
Jang, J. W., Choi, J. Y., Bae, S. H., Yoon, S. K., Chang, I. U., Kim, C. W., Cho, S. H., Han, J. Y., & Lee, Y. S. (2006). A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. https://doi.org/10.1002/hep.21024

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.